- Home
- SPRY vs CIM Comparison
SPRY vs CIM Comparison
Compare SPRY & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- CIM
- Stock Information
- Founded
- SPRY 2015
- CIM 2007
- Country
- SPRY United States
- CIM United States
- Employees
- SPRY N/A
- CIM N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- SPRY Health Care
- CIM Real Estate
- Exchange
- SPRY Nasdaq
- CIM Nasdaq
- Market Cap
- SPRY 1.4B
- CIM 1.1B
- IPO Year
- SPRY N/A
- CIM 2007
- Fundamental
- Price
- SPRY $15.69
- CIM $13.74
- Analyst Decision
- SPRY Strong Buy
- CIM Buy
- Analyst Count
- SPRY 4
- CIM 3
- Target Price
- SPRY $28.75
- CIM $15.50
- AVG Volume (30 Days)
- SPRY 1.2M
- CIM 492.8K
- Earning Date
- SPRY 08-05-2025
- CIM 08-06-2025
- Dividend Yield
- SPRY N/A
- CIM 10.82%
- EPS Growth
- SPRY N/A
- CIM N/A
- EPS
- SPRY N/A
- CIM 1.52
- Revenue
- SPRY $97,122,000.00
- CIM $326,755,000.00
- Revenue This Year
- SPRY N/A
- CIM $18.94
- Revenue Next Year
- SPRY $140.40
- CIM $3.05
- P/E Ratio
- SPRY N/A
- CIM $9.00
- Revenue Growth
- SPRY 971120.00
- CIM 11.90
- 52 Week Low
- SPRY $7.55
- CIM $9.85
- 52 Week High
- SPRY $18.51
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- SPRY 60.81
- CIM 55.98
- Support Level
- SPRY $14.77
- CIM $13.54
- Resistance Level
- SPRY $16.23
- CIM $14.34
- Average True Range (ATR)
- SPRY 0.73
- CIM 0.27
- MACD
- SPRY 0.12
- CIM -0.03
- Stochastic Oscillator
- SPRY 84.68
- CIM 56.16
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.